{"title":"尼日利亚人口主动脉瓣硬化和退行性瓣膜疾病:超声心动图研究。","authors":"Olugbenga O Abiodun, Ibrahim L Salau, Tina Anya","doi":"10.5334/gh.1455","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The burden of degenerative valve disease is increasing globally because of population aging. However, data on this condition is scarce in Nigeria and across Africa.</p><p><strong>Objective: </strong>Our study evaluated the prevalence, pattern, and associations of aortic sclerosis and degenerative valve disease in a Nigerian population.</p><p><strong>Methods: </strong>Data of a total of 4030 patients were analyzed retrospectively from the Federal Medical Centre Abuja transthoracic echocardiographic registry from January 2020 to December 2024. Patients were 18 years and above. Aortic sclerosis, degenerative mitral valve disease, calcific aortic valve disease, and degenerative valve disease were defined in accordance with the report of the American Heart Association/American College of Cardiology guidelines.</p><p><strong>Results: </strong>The mean age of patients was 52 ± 15 years and 53.2% were female. The prevalence rates were 4.2% for aortic sclerosis, 0.2% for degenerative mitral valve disease, 1.2% for calcific aortic valve disease, and 1.3% for degenerative valve disease. Among patients aged 65 years and older, the prevalences rates were higher for aortic sclerosis (13.2%), degenerative mitral valve disease (1.0%), calcific aortic valve disease (3.4%), and degenerative valve disease (3.9%) [<i>P</i> < 0.001]. Only 1.7% and 0.6% of those <65 years had aortic sclerosis and calcific aortic valve disease, respectively. Patients aged 65 years and older, and hypertension had odds ratio (OR) of 7.99 and 3.98 for developing aortic sclerosis, respectively. For calcific aortic valve disease, the OR was higher for patients aged 65 years and older (OR: 4.25), hypertension (OR: 2.48), and left ventricular hypertrophy (OR: 5.35) [<i>P</i> < 0.001].</p><p><strong>Conclusion: </strong>In this Nigerian echocardiographic registry, age above 65 years and hypertension were associated with aortic sclerosis and calcific aortic valve disease.</p>","PeriodicalId":56018,"journal":{"name":"Global Heart","volume":"20 1","pages":"67"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372657/pdf/","citationCount":"0","resultStr":"{\"title\":\"Aortic Valve Sclerosis and Degenerative Valve Disease in a Nigerian Population: An Echocardiographic Study.\",\"authors\":\"Olugbenga O Abiodun, Ibrahim L Salau, Tina Anya\",\"doi\":\"10.5334/gh.1455\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The burden of degenerative valve disease is increasing globally because of population aging. However, data on this condition is scarce in Nigeria and across Africa.</p><p><strong>Objective: </strong>Our study evaluated the prevalence, pattern, and associations of aortic sclerosis and degenerative valve disease in a Nigerian population.</p><p><strong>Methods: </strong>Data of a total of 4030 patients were analyzed retrospectively from the Federal Medical Centre Abuja transthoracic echocardiographic registry from January 2020 to December 2024. Patients were 18 years and above. Aortic sclerosis, degenerative mitral valve disease, calcific aortic valve disease, and degenerative valve disease were defined in accordance with the report of the American Heart Association/American College of Cardiology guidelines.</p><p><strong>Results: </strong>The mean age of patients was 52 ± 15 years and 53.2% were female. The prevalence rates were 4.2% for aortic sclerosis, 0.2% for degenerative mitral valve disease, 1.2% for calcific aortic valve disease, and 1.3% for degenerative valve disease. Among patients aged 65 years and older, the prevalences rates were higher for aortic sclerosis (13.2%), degenerative mitral valve disease (1.0%), calcific aortic valve disease (3.4%), and degenerative valve disease (3.9%) [<i>P</i> < 0.001]. Only 1.7% and 0.6% of those <65 years had aortic sclerosis and calcific aortic valve disease, respectively. Patients aged 65 years and older, and hypertension had odds ratio (OR) of 7.99 and 3.98 for developing aortic sclerosis, respectively. For calcific aortic valve disease, the OR was higher for patients aged 65 years and older (OR: 4.25), hypertension (OR: 2.48), and left ventricular hypertrophy (OR: 5.35) [<i>P</i> < 0.001].</p><p><strong>Conclusion: </strong>In this Nigerian echocardiographic registry, age above 65 years and hypertension were associated with aortic sclerosis and calcific aortic valve disease.</p>\",\"PeriodicalId\":56018,\"journal\":{\"name\":\"Global Heart\",\"volume\":\"20 1\",\"pages\":\"67\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-08-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372657/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Heart\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5334/gh.1455\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Heart","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5334/gh.1455","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Aortic Valve Sclerosis and Degenerative Valve Disease in a Nigerian Population: An Echocardiographic Study.
Background: The burden of degenerative valve disease is increasing globally because of population aging. However, data on this condition is scarce in Nigeria and across Africa.
Objective: Our study evaluated the prevalence, pattern, and associations of aortic sclerosis and degenerative valve disease in a Nigerian population.
Methods: Data of a total of 4030 patients were analyzed retrospectively from the Federal Medical Centre Abuja transthoracic echocardiographic registry from January 2020 to December 2024. Patients were 18 years and above. Aortic sclerosis, degenerative mitral valve disease, calcific aortic valve disease, and degenerative valve disease were defined in accordance with the report of the American Heart Association/American College of Cardiology guidelines.
Results: The mean age of patients was 52 ± 15 years and 53.2% were female. The prevalence rates were 4.2% for aortic sclerosis, 0.2% for degenerative mitral valve disease, 1.2% for calcific aortic valve disease, and 1.3% for degenerative valve disease. Among patients aged 65 years and older, the prevalences rates were higher for aortic sclerosis (13.2%), degenerative mitral valve disease (1.0%), calcific aortic valve disease (3.4%), and degenerative valve disease (3.9%) [P < 0.001]. Only 1.7% and 0.6% of those <65 years had aortic sclerosis and calcific aortic valve disease, respectively. Patients aged 65 years and older, and hypertension had odds ratio (OR) of 7.99 and 3.98 for developing aortic sclerosis, respectively. For calcific aortic valve disease, the OR was higher for patients aged 65 years and older (OR: 4.25), hypertension (OR: 2.48), and left ventricular hypertrophy (OR: 5.35) [P < 0.001].
Conclusion: In this Nigerian echocardiographic registry, age above 65 years and hypertension were associated with aortic sclerosis and calcific aortic valve disease.
Global HeartMedicine-Cardiology and Cardiovascular Medicine
CiteScore
5.70
自引率
5.40%
发文量
77
审稿时长
5 weeks
期刊介绍:
Global Heart offers a forum for dialogue and education on research, developments, trends, solutions and public health programs related to the prevention and control of cardiovascular diseases (CVDs) worldwide, with a special focus on low- and middle-income countries (LMICs). Manuscripts should address not only the extent or epidemiology of the problem, but also describe interventions to effectively control and prevent CVDs and the underlying factors. The emphasis should be on approaches applicable in settings with limited resources.
Economic evaluations of successful interventions are particularly welcome. We will also consider negative findings if important. While reports of hospital or clinic-based treatments are not excluded, particularly if they have broad implications for cost-effective disease control or prevention, we give priority to papers addressing community-based activities. We encourage submissions on cardiovascular surveillance and health policies, professional education, ethical issues and technological innovations related to prevention.
Global Heart is particularly interested in publishing data from updated national or regional demographic health surveys, World Health Organization or Global Burden of Disease data, large clinical disease databases or registries. Systematic reviews or meta-analyses on globally relevant topics are welcome. We will also consider clinical research that has special relevance to LMICs, e.g. using validated instruments to assess health-related quality-of-life in patients from LMICs, innovative diagnostic-therapeutic applications, real-world effectiveness clinical trials, research methods (innovative methodologic papers, with emphasis on low-cost research methods or novel application of methods in low resource settings), and papers pertaining to cardiovascular health promotion and policy (quantitative evaluation of health programs.